Showing 2981-2990 of 5956 results for "".
- House Subcommittee Urges FTC to Modernize Contact Lens Verification Processhttps://modernod.com/news/house-subcommittee-urges-ftc-to-modernize-contact-lens-verification-process/2476657/The Health Care Alliance for Patient Safety expressed its support of the House Committee on Appropriations for urging the Federal Trade Commission (FTC) to update the process by which contact lens prescriptions are verified, according to a news
- Valeda Light Delivery System Receives 2019 Medical Design Excellence Awardhttps://modernod.com/news/valeda-light-delivery-system-receives-2019-medical-design-excellence-award/2476654/LumiThera and Product Creation Studio announced that LumiThera’s Valeda Light Delivery System has won a silver award in the 21st Annual Medical Design Excellence Awards competition. The 2019 winners were announced at the MDEA Ceremony on Tuesday, June 11, 2
- First Patient Dosed in Phase 2 Trial Evaluating Ocular Delivery of ST266 For the Treatment of Persistent Corneal Epithelial Defectshttps://modernod.com/news/noveome-biotherapeutics-announces-the-first-patient-dosed-in-phase-2-open-label-clinical-trial-evaluating-topical-ocular-delivery-of-st266-for-the-treatment-of-persistent-corneal-epithelial-defects/2476652/Noveome Biotherapeutics announced the dosing of the first patient in its phase 2 open label, multicenter clinical trial evaluating topical ocular delivery of ST266 for the treatment of persistent corneal epithelial defects (PEDs), for which there are limited treatment options. “The dosing
- First Subject Enrolled in Trial to Confirm Safety and Efficacy of TearCare Device for Dry Eyehttps://modernod.com/news/first-subject-enrolled-in-large-trial-to-confirm-safety-and-efficacy-of-dry-eye-treatment-device-tearcare/2476650/Sight Sciences announced the first subject has been enrolled in OLYMPIA, a US pivotal trial to further assess the safety and efficacy of TearCare for patients with dry eye disease. TearCare is a wearable, personalized, open-eye technology that delivers regu
- Roche’s Purchase of Spark Therapeutics Faces Further Delay Amid Scrutiny From US, UK Regulatorshttps://modernod.com/news/roches-purchase-of-spark-therapeutics-faces-further-delay-amid-scrutiny-from-us-uk-regulators/2476640/The US Federal Trade Commission requested additional information and documentary material from Roche and Spark Therapeutics in connection with its review of the companies’ pending deal, the drugmakers reported Monday. Roche noted that as a result, its $4.3-billion offer to acquire Spark has
- EyePoint Pharmaceuticals Names New Members of Executive Leadership Teamhttps://modernod.com/news/eyepoint-pharmaceuticals-names-new-members-of-executive-leadership-team/2476642/EyePoint Pharmaceuticals announced the appointment of Scott Jones as Chief Commercial Officer and Said Saim, PhD, as Chief Technology Officer. Mr. Jones will be responsible for the commercialization of Dexycu (dexamethasone intraocular suspension) 9% for the treatment of postoperative inflammatio
- Medical Specialty Organizations Applaud Introduction of Congressional Legislation to Improve Transparency in Prior Authorizationhttps://modernod.com/news/medical-specialty-organizations-applaud-introduction-of-congressional-legislation-to-improve-oversight-and-transparency-in-prior-authorization/2476633/A coalition of eight national medical specialties, including the American Academy of Ophthalmology, pledged support for the bipartisan “Improving Seniors’ Timely Access to Care Act of 2019” (H.R. 3107) legislation that aims to protect patients from unreasonable Medicare Advantag
- Goldman Sachs Unit to Buy 575 Optometry Practices in $2.7 Billion Dealhttps://modernod.com/news/report-goldman-sachs-unit-to-buy-capital-vision-services-in-2-7-billion-deal/2476625/In one of the largest optometry deals to date, the merchant-banking division of Goldman Sachs Group (West Street Capital Partners VII) announced that it is buying Capital Vision Services, which operates 575 optometry practices, from private-equity firm Altas Partners LP and Canadian pension fund
- OptiKira Awarded Phase 2 SBIR Grant to Support Development of Retinitis Pigmentosa Treatmenthttps://modernod.com/news/optikira-awarded-phase-2-sbir-grant-to-support-development-of-retinitis-pigmentosa-treatment/2476622/OptiKira announced that it was awarded a phase 2 Small Business Innovation Research (SBIR) grant to support continued development of a therapy that has the potential to preserve vision in patients with retinitis pigmentosa (RP). The $1.6M grant will be used to advance one or more of OptiKira’s mo
- Seniors With Vision Loss Experience Discrimination, Depressionhttps://modernod.com/news/seniors-with-vision-loss-experience-discrimination-depression/2476623/Seniors with declining vision are more likely than peers with good eyesight to experience discrimination as well as depression that may result from this bias, a new study from the UK suggests, according to a Reuters report. After s